Drug intelligence / Profile preview

PPC 17

Development stage: Preclinical
Lead developer: Phytomyco Research
Modality: Small Molecules

Overview

PPC 17 is a preclinical-stage anti-infective agent being developed by Phytomyco Research. It is a small molecule derived from a natural product source, specifically designed to target *Pseudomonas aeruginosa* infections. The drug is currently undergoing animal-level preclinical testing to evaluate its efficacy and safety as a potential treatment for Pseudomonas-related infections. As a natural product-based therapeutic, it represents an effort to identify novel antibacterial scaffolds to combat antibiotic-resistant pathogens.

Beyond the preview

Go deeper on PPC 17.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PPC 17.

Explore the full profile